1-6 of 6
Danielle Brander
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Free
Jennifer Woyach, Danielle Brander, Boyu Hu, Kerry Rogers, Zulfa Omer, Emily Curran, Deborah Stephens, Andrea Sitlinger, Yi Chen, Stephen Anthony, Yu Chen, Kewei Shang, John Byrd
Journal: Blood
Blood (2025) 146 (Supplement 1): 87.
https://doi.org/10.1182/blood-2025-87
Published: 2025
Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Free
Zulfa Omer, Alexey Danilov, Francesco Forconi, Talha Munir, Mary Gleeson, Nirav Shah, Graham Collins, Alvaro Alencar, Jane Robertson, Jonathon Cohen, Karan Dixit, Danielle Brander, John Byrd, Allison Winter, Jeffery Smith, Dima El-Sharkawi, Michal Kwiatek, Iwona Hus, Prioty Islam, Sebastian Grosicki, Michael Tees, Thorsten Zenz, Joanna Romejko-Jarosinska, Sarah Injac, Wojciech Jurczak
Journal: Blood
Blood (2025) 146 (Supplement 1): 86.
https://doi.org/10.1182/blood-2025-86
Published: 2025
Journal Articles

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Free
Nitin Jain, Catherine Coombs, James D'Olimpio, Nirav Shah, Jacqueline Barrientos, Seung Tae Lee, Danielle Brander, John Nemunaitis, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Koji Yoshida, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William Wierda, Varsha Gandhi, Javier Pinilla-Ibarz
Journal: Blood
Blood (2025) 146 (Supplement 1): 3892.
https://doi.org/10.1182/blood-2025-3892
Published: 2025
Journal Articles

Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry

Free
Nilanjan Ghosh, Jeff P. Sharman, Jacqueline C. Barrientos, Danielle Brander, Meghan Gutierrez, Linda Wu, Zaina P. Qureshi, Sandhya Upasani, Maoko Naganuma, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 7047–7049.
https://doi.org/10.1182/blood-2022-155649
Published: 2022
Journal Articles

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Free
Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle Brander, Michael Tees, Sameer A. Parikh, Tycel J. Phillips, Razi Ghori, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens
Journal: Blood
Blood (2022) 140 (Supplement 1): 7004–7006.
https://doi.org/10.1182/blood-2022-163596
Published: 2022
Journal Articles

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Free
Cecilia Bonolo De Campos, Chantal McCabe, Laura Ann Bruins, Daniel R. O'Brien, Sochilt Brown, Cristine Allmer, Yuan Xiao Zhu, Kari G Rabe, Sameer A. Parikh, Neil E. Kay, James R. Cerhan, Laura Z Rassenti, Richard R. Furman, J. Brice Weinberg, Danielle Brander, Marta Chesi, Susan L. Slager, Esteban Braggio
Journal: Blood
Blood (2022) 140 (Supplement 1): 4135–4136.
https://doi.org/10.1182/blood-2022-170944
Published: 2022